quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:01:04·45d
INSIDERFiling
Tango Therapeutics Inc. logo

President, R&D Crystal Adam sold $303,765 worth of shares (20,251 units at $15.00), decreasing direct ownership by 15% to 112,622 units (SEC Form 4)

TNGX· Tango Therapeutics Inc.
Health Care
Original source

Companies

  • TNGX
    Tango Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 3UpdateCanaccord Genuity$30.00
  • Apr 2UpdateCanaccord Genuity$30.00
  • Feb 23UpdateMizuho$19.00
  • Nov 18UpdateWolfe Research-
  • Aug 19UpdatePiper Sandler$11.00
  • Jul 17UpdateJefferies$19.00

Related

  • SEC7d
    SEC Form DEFA14A filed by Tango Therapeutics Inc.
  • SEC7d
    SEC Form DEF 14A filed by Tango Therapeutics Inc.
  • INSIDER7d
    SEC Form 4 filed by Crystal Adam
  • SEC9d
    Tango Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR9d
    Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
  • ANALYST21d
    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target
  • INSIDER21d
    SEC Form 4 filed by Crystal Adam
  • ANALYST22d
    Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022